Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)

China · Delayed Price · Currency is CNY

4.850

+0.500 (11.49%)

Nov 5, 2026, 3:04 PM CST

Market Cap	3.21B -51.4%
Revenue (ttm)	1.51B +2.9%
Net Income	-1.45B
EPS	-2.18
Shares Out	661.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,565,398
Open	4.850
Previous Close	4.350
Day's Range	4.280 - 4.990
52-Week Range	3.910 - 11.230
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, asia diet sarsae, asia juice soda, asia soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides m... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1986

Employees 2,662

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300147

Full Company Profile

Financial Performance

In 2025, Xiangxue Pharmaceutical's revenue was 1.60 billion, a decrease of -14.16% compared to the previous year's 1.86 billion. Losses were -1.39 billion, 62.2% more than in 2024.

Financial Statements